MRI在早期帕金森病診斷中的價值_《華西醫學》

作者：

廖悄 ¹ , 李楠楠 ¹ ,  彭蓉 ²

關鍵詞：

帕金森病磁共振成像早期診斷

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

MRI因其無創性及對大腦解剖結構清晰的成像在神經系統變形疾病中得到廣泛的應用。過去二十年中，功能性磁共振技術在常規MRI的基礎上迅速發展起來。這些新的MRI技術提供大腦物質能量代謝、功能區體積測量和灌注等方面的信息，使得MRI在研究疾病的病理生理、分子學水平得到很大提高。現結合近幾年國內外研究，對MRI在早期帕金森病診斷中的價值作一綜述。

引用本文： 廖悄,李楠楠,彭蓉. MRI在早期帕金森病診斷中的價值. 華西醫學, 2012, 27(11): 1733-1736. doi: 復制

1.	Mahlknecht P, Hotter A, Hussl A, et al. Significance of MRI in diagnosis and differential diagnosis of Parkinson’s disease[J]. Neurodegener Dis, 2010, 7(5): 300-318.
2.	Baudrexel S, Klein JC, Deichmann R, et al. Innovative MRI techniques in Parkinson’s disease[J]. Nervenarzt, 2010, 81(10): 1180-1188.
3.	Schuff N. Potential role of high-field MRI for studies in Parkinson’s disease[J]. Mov Disord, 2009, 24 Suppl 2(2): S684-S690.
4.	Cho ZH, Oh SH, Kim JM, et al. Direct visualization of Parkinson’s disease by in vivo human brain imaging using 7.0T magnetic resonance imaging[J]. Mov Disord, 2011, 26(4): 713-718.
5.	Brenneis C, Seppi K, Schocke MF, et al. Voxel-based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy[J]. Mov Disord, 2003, 18(10): 1132-1138.
6.	Geng DY, Li YX, Zee CS. Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson’s disease[J]. Neurosurgery, 2006, 58(2): 256-262.
7.	Borghammer P, ?stergaard K, Cumming P, et al. A deformation-based morphometry study of patients with early-stage Parkinson’s disease[J]. Eur J Neurol, 2010, 17(2): 314-320.
8.	Matthews PM, Jezzard P. Functional magnetic resonance imaging[J]. J Neurol Neurosurg Psychiatry, 2004, 75(1): 6-12.
9.	Prodoehl J, Spraker M, Corcos D, et al. Blood oxygenation level-dependent activation in basal ganglia nuclei relates to specific symptoms in de novo Parkinson’s disease[J]. Mov Disord, 2010, 25(13): 2035-2043.
10.	Moraschi M, Giulietti G, Giove F, et al. fMRI study of motor cortex activity modulation in early Parkinson’s disease[J]. Magn Reson Imaging, 2010, 28(8): 1152-1158.
11.	Haacke EM, Ye Y. The role of susceptibility weighted imaging in functional MRI [J]. Neuroimage, 2012, 62(2): 923-929.
12.	Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson’s disease[J]. Mov Disord, 2011, 26(6): 1049-1055.
13.	Hill JM, Ruff MR, Weber RJ, et al. Transferrin receptors in rat brain: neuropeptide-like pattern and relationship to Iron distribution[J]. Proc Natl Acad Sci U S A, 1985, 82(13): 4553-4557.
14.	Lotfipour AK, Wharton S, Schwarz ST, et al. High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson’s disease[J]. J Magn Reson Imaging, 2012, 35(1): 48-55.
15.	Zhang W, Sun SG, Jiang YH, et al. Determination of brain Iron content in patients with Parkinson’s disease using magnetic susceptibility imaging[J]. Neurosci Bull, 2009, 25(6): 353-360.
16.	Schocke MF, Seppi K, Esterhammer R, et al. Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson’s disease[J]. Neuroimage, 2004, 21(4): 1443-1451.
17.	Scherfler C, Schocke MF, Seppi K, et al. Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson’s disease[J]. Brain, 2006, 129(Pt 2): 538-542.
18.	Rolheiser TM, Fulton HG, Good KP, et al. Diffusion tensor imaging and olfactory identification testing in early-stage Parkinson’s disease[J]. J Neurol, 2011, 258(7): 1254-1260.
19.	Gaudiello F, Garaci FG, Marziali S, et al. Evaluation of basal ganglia haemodynamic changes with perfusion-weighted magnetic resonance imaging in patients with Parkinson’s disease[J]. Radiol Med, 2006, 111(2): 284-290.
20.	Melzer TR, Watts R, Macaskill MR, et al. Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson’s disease[J]. Brain, 2011, 134(Pt 3): 845-855.
21.	Rango M, Arighi A, Biondetti P, et al. Magnetic resonance spectroscopy in Parkinson’s disease and parkinsonian syndromes[J]. Funct Neurol, 2007, 22(2): 75-79.
22.	Hattingen E, Magerkurth J, Pilatus U, et al. Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson’s disease[J]. Brain, 2009, 132(Pt 12): 3285-3297.
23.	Michell AW, Lewis SG, Foltynie T, et al. Biomarkers and parkinson’s disease[J]. Brain, 2004, 127(8): 1693-1705.
24.	Lucetti C, Del Dotto P, Gambaccini G, et al. Proton magnetic resonance spectroscopy (1H-MRS) of motor cortex and basal ganglia in de novo Parkinson’s disease patients[J]. Neurol Sci, 2001, 22(1): 69-70.
25.	Gupta D, Saini J, Kesavadas C, et al. Utility of susceptibility-weighted MRI in differentiating Parkinson’s disease and atypical parkinsonism[J]. Neuroradiology, 2010, 52(12): 1087-1094.
26.	Mahlknecht P, Schocke M, Seppi K. Differential diagnosis of parkinsonian syndromes using MRI[J]. Nervenarzt, 2010, 81(10): 1168-1179.
27.	Seppi K, Schocke MF, Esterhammer R, et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy[J]. Neurology, 2003, 60(6): 922-927.
28.	Boelmans K, Bodammer NC, Suchorska B, et al. Diffusion tensor imaging of the corpus callosum differentiates corticobasal syndrome from Parkinson’s disease[J]. Parkinsonism Relat Disord, 2010, 16(8): 498-502.
29.	Schocke MF, Seppi K, Esterhammer R, et al. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD[J]. Neurology, 2002, 58(4): 575-580.
30.	Nicoletti G, Lodi R, Condino F, et al. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson’s disease and progressive supranuclear palsy[J]. Brain, 2006, 129(Pt 10): 2679-2687.

1. 　Mahlknecht P, Hotter A, Hussl A, et al. Significance of MRI in diagnosis and differential diagnosis of Parkinson’s disease[J]. Neurodegener Dis, 2010, 7(5): 300-318.
2. 　Baudrexel S, Klein JC, Deichmann R, et al. Innovative MRI techniques in Parkinson’s disease[J]. Nervenarzt, 2010, 81(10): 1180-1188.
3. 　Schuff N. Potential role of high-field MRI for studies in Parkinson’s disease[J]. Mov Disord, 2009, 24 Suppl 2(2): S684-S690.
4. 　Cho ZH, Oh SH, Kim JM, et al. Direct visualization of Parkinson’s disease by in vivo human brain imaging using 7.0T magnetic resonance imaging[J]. Mov Disord, 2011, 26(4): 713-718.
5. 　Brenneis C, Seppi K, Schocke MF, et al. Voxel-based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy[J]. Mov Disord, 2003, 18(10): 1132-1138.
6. 　Geng DY, Li YX, Zee CS. Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson’s disease[J]. Neurosurgery, 2006, 58(2): 256-262.
7. 　Borghammer P, ?stergaard K, Cumming P, et al. A deformation-based morphometry study of patients with early-stage Parkinson’s disease[J]. Eur J Neurol, 2010, 17(2): 314-320.
8. 　Matthews PM, Jezzard P. Functional magnetic resonance imaging[J]. J Neurol Neurosurg Psychiatry, 2004, 75(1): 6-12.
9. 　Prodoehl J, Spraker M, Corcos D, et al. Blood oxygenation level-dependent activation in basal ganglia nuclei relates to specific symptoms in de novo Parkinson’s disease[J]. Mov Disord, 2010, 25(13): 2035-2043.
10. 　Moraschi M, Giulietti G, Giove F, et al. fMRI study of motor cortex activity modulation in early Parkinson’s disease[J]. Magn Reson Imaging, 2010, 28(8): 1152-1158.
11. 　Haacke EM, Ye Y. The role of susceptibility weighted imaging in functional MRI [J]. Neuroimage, 2012, 62(2): 923-929.
12. 　Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson’s disease[J]. Mov Disord, 2011, 26(6): 1049-1055.
13. 　Hill JM, Ruff MR, Weber RJ, et al. Transferrin receptors in rat brain: neuropeptide-like pattern and relationship to Iron distribution[J]. Proc Natl Acad Sci U S A, 1985, 82(13): 4553-4557.
14. 　Lotfipour AK, Wharton S, Schwarz ST, et al. High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson’s disease[J]. J Magn Reson Imaging, 2012, 35(1): 48-55.
15. 　Zhang W, Sun SG, Jiang YH, et al. Determination of brain Iron content in patients with Parkinson’s disease using magnetic susceptibility imaging[J]. Neurosci Bull, 2009, 25(6): 353-360.
16. 　Schocke MF, Seppi K, Esterhammer R, et al. Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson’s disease[J]. Neuroimage, 2004, 21(4): 1443-1451.
17. 　Scherfler C, Schocke MF, Seppi K, et al. Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson’s disease[J]. Brain, 2006, 129(Pt 2): 538-542.
18. 　Rolheiser TM, Fulton HG, Good KP, et al. Diffusion tensor imaging and olfactory identification testing in early-stage Parkinson’s disease[J]. J Neurol, 2011, 258(7): 1254-1260.
19. 　Gaudiello F, Garaci FG, Marziali S, et al. Evaluation of basal ganglia haemodynamic changes with perfusion-weighted magnetic resonance imaging in patients with Parkinson’s disease[J]. Radiol Med, 2006, 111(2): 284-290.
20. 　Melzer TR, Watts R, Macaskill MR, et al. Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson’s disease[J]. Brain, 2011, 134(Pt 3): 845-855.
21. 　Rango M, Arighi A, Biondetti P, et al. Magnetic resonance spectroscopy in Parkinson’s disease and parkinsonian syndromes[J]. Funct Neurol, 2007, 22(2): 75-79.
22. 　Hattingen E, Magerkurth J, Pilatus U, et al. Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson’s disease[J]. Brain, 2009, 132(Pt 12): 3285-3297.
23. 　Michell AW, Lewis SG, Foltynie T, et al. Biomarkers and parkinson’s disease[J]. Brain, 2004, 127(8): 1693-1705.
24. 　Lucetti C, Del Dotto P, Gambaccini G, et al. Proton magnetic resonance spectroscopy (1H-MRS) of motor cortex and basal ganglia in de novo Parkinson’s disease patients[J]. Neurol Sci, 2001, 22(1): 69-70.
25. 　Gupta D, Saini J, Kesavadas C, et al. Utility of susceptibility-weighted MRI in differentiating Parkinson’s disease and atypical parkinsonism[J]. Neuroradiology, 2010, 52(12): 1087-1094.
26. 　Mahlknecht P, Schocke M, Seppi K. Differential diagnosis of parkinsonian syndromes using MRI[J]. Nervenarzt, 2010, 81(10): 1168-1179.
27. 　Seppi K, Schocke MF, Esterhammer R, et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy[J]. Neurology, 2003, 60(6): 922-927.
28. 　Boelmans K, Bodammer NC, Suchorska B, et al. Diffusion tensor imaging of the corpus callosum differentiates corticobasal syndrome from Parkinson’s disease[J]. Parkinsonism Relat Disord, 2010, 16(8): 498-502.
29. 　Schocke MF, Seppi K, Esterhammer R, et al. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD[J]. Neurology, 2002, 58(4): 575-580.
30. 　Nicoletti G, Lodi R, Condino F, et al. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson’s disease and progressive supranuclear palsy[J]. Brain, 2006, 129(Pt 10): 2679-2687.

《華西醫學》

MRI在早期帕金森病診斷中的價值

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《華西醫學》

MRI在早期帕金森病診斷中的價值

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料